UBS Group’s Propanc Biopharma PPCB Stock Holding History

UBS Group’s Portfolio PPCB Stock Details PPCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,305	Closed	-$19.4K	–	11500
2026 Q1	$19.4K	Buy	+7,305	New	+$43.4K	﹤0.01%	7960

Other funds holding PPCB

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's PPCB Position: Q2 2026 in Review

UBS Group sold out of Propanc Biopharma (PPCB) in Q2 2026, closing a stake of 7,305 shares — an estimated $19.4K sold.

UBS Group first reported a position in PPCB in Q1 2026 and held it in 1 quarter. The position peaked at $19.4K in Q1 2026. 4 funds tracked by Wall St. Rank hold PPCB as of Q2 2026.

UBS Group reported no remaining Propanc Biopharma position as of Q2 2026 after selling out during the quarter.
UBS Group sold 7,305 Propanc Biopharma shares in Q2 2026, an estimated $19.4K.
UBS Group first reported a position in Propanc Biopharma in Q1 2026 and held it in 1 quarter.
UBS Group's Propanc Biopharma position peaked at $19.4K in Q1 2026.
4 funds tracked by Wall St. Rank held Propanc Biopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.